Analysis of the epitope and neutralizing capacity of human monoclonal antibodies induced by hepatitis B vaccine.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Antiviral Research

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.antiviral.2010.04.006PMID 20412816
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Control of hepatitis B virus replication by innate response of HepaRG cells

  2010cited by this paper
• A rapid and efficient single-cell manipulation method for screening antigen-specific antibody–secreting cells from human peripheral blood

  2009influential reference
• Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees.

  2008cited by this paper
• Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized Double‐Blind, Placebo‐Controlled Trial

  2007cited by this paper
• Human monoclonal antibody against Hepatitis B virus surface antigen (HBsAg).

  2007cited by this paper
• Viral and cellular determinants involved in hepadnaviral entry.

  2007cited by this paper
• Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor

  2007cited by this paper
• Single lymphocyte analysis with a microwell array chip

  2007influential reference
• Cell‐microarray analysis of antigen‐specific B‐cells: Single cell analysis of antigen receptor expression and specificity

  2007influential reference
• Entry of Hepatitis Delta Virus Requires the Conserved Cysteine Residues of the Hepatitis B Virus Envelope Protein Antigenic Loop and Is Blocked by Inhibitors of Thiol-Disulfide Exchange

  2007cited by this paper
• The immune response induced by hepatitis B virus principal antigens.

  2006cited by this paper
• Amplification and analysis of cDNA generated from a single cell by 5'-RACE: application to isolation of antibody heavy and light chain variable gene sequences from single B cells.

  2006cited by this paper
• Evaluation of murine monoclonal antibodies targeting different epitopes of the hepatitis B virus surface antigen by using immunological as well as molecular biology and biochemical approaches.

  2006cited by this paper
• Role of the Antigenic Loop of the Hepatitis B Virus Envelope Proteins in Infectivity of Hepatitis Delta Virus

  2005cited by this paper
• Hepatitis B virus infection--natural history and clinical consequences.

  2004cited by this paper
• Epidemiology and Prevention of Hepatitis B

  2003cited by this paper
• EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

  2003influential reference
• Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties

  2002cited by this paper
• Infection of a human hepatoma cell line by hepatitis B virus

  2002cited by this paper
• Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

  2002cited by this paper
• Preclinical Evaluation of Two Human Anti–Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV‐Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees

  2000cited by this paper
• Hepatitis B Virus Biology

  2000cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999influential reference
• Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

  1998cited by this paper
• Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy

  1998cited by this paper
• Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb

  1998cited by this paper
• Role of the Pre-S2 Domain of the Large Envelope Protein in Hepatitis B Virus Assembly and Infectivity

  1998cited by this paper
• The clinical significance of surface antigen variants of hepatitis B virus

  1997influential reference
• Identification and characterization of a C(K/R)TC motif as a common epitope present in all subtypes of hepatitis B surface antigen.

  1996cited by this paper
• Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library.

  1996cited by this paper
• Efficient production of anti-(hepatitis B virus) antibodies and their neutralizing activity in chimpanzees

  1995cited by this paper
• Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein

  1993cited by this paper
• IgG subclass distribution of anti-HBs antibodies following vaccination with cDNA HBsAg.

  1992cited by this paper
• A topological model for hepatitis B surface antigen.

  1992influential reference
• Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response.

  1992cited by this paper
• Epitope mapping of HBsAg using a panel of human anti-HBs antibodies.

  1991cited by this paper
• Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus.

  1986cited by this paper
• [Epidemiology and prevention of hepatitis].

  1975cited by this paper
• Australia Antigen (Hepatitis B Antigen): A Conformational Antigen Dependent on Disulfide Bonds

  1972cited by this paper

• Chemoenzymatic Synthesis of Nanobody-Peptide Conjugates Capable of Harnessing HBV Vaccine-Induced Antibodies for Cancer Immunotherapy.

  2026cites this paper
• Characterisation of plasmablast-derived HBsAg-specific antibody and its structural basis for binding to native HBsAg dimer

  2026cites this paper
• Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors.

  2025cites this paper
• Engineered Nanobody Chimeras Recruits Anti-HBV Antibodies for Target Cancer Immunotherapy.

  2025cites this paper
• In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus.

  2025cites this paper
• Screening and identification of human HPV18VLP neutralizing antibodies from women receiving HPV vaccine

  2025cites this paper
• Circulating HBsAg-specific B cells are partially rescued in chronically HBV-infected patients with functional cure

  2024cites this paper
• Impact of preS1 Evaluation in the Management of Chronic Hepatitis B Virus Infection

  2024cites this paper
• CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells

  2024cites this paper
• A Design of mRNA-Based COVID-19 Vaccine Through Fuzzy Neural Network

  2023cites this paper
• Pre‐existing immunity to SARS‐CoV‐2 associates with strong T cell responses induced by inactivated COVID‐19 vaccines

  2023cites this paper
• Screening of potential antigens from whole proteome and development of multi-epitope vaccine against Rhizopus delemar using immunoinformatics approaches

  2022cites this paper
• Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis

  2022cites this paper
• Longitudinal mapping of hepatitis B vaccine‐induced B‐cell linear epitopes in healthy individuals

  2022cites this paper
• Advances in human monoclonal antibody therapy for HBV infection.

  2022cites this paper
• O-glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection.

  2021cites this paper
• The dynamics and association of B and T cell receptor repertoires upon antibody response to hepatitis B vaccination in healthy adults

  2021cites this paper
• A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.

  2020cites this paper
• In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of possible putative protective effect

  2020cites this paper
• Potential T-cell and B-cell Epitopes of 2019-nCoV

  2020cites this paper
• In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect

  2020cites this paper
• Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity

  2020cites this paper
• Cross-Protection of Hepatitis B Vaccination among Different Genotypes

  2020cites this paper
• Hepatitis B Vaccination Induces Mucosal Antibody Responses in the Female Genital Tract, Indicating Potential Mechanisms of Protection Against Infection

  2019cites this paper
• Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications.

  2019cites this paper
• An E. coli‐produced single‐chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion

  2019cites this paper
• Next-generation sequencing analysis of the human T-cell and B-cell receptor repertoire diversity before and after hepatitis B vaccination

  2019cites this paper
• Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus

  2019cites this paper
• 首都圏におけるB型急性肝炎の変遷：―Genotype Aの急増から10年を経て―

  2019cites this paper
• Efficient Acquisition of Fully Human Antibody Genes against Self-Proteins by Sorting Single B Cells Stimulated with Vaccines Based on Nitrated T Helper Cell Epitopes

  2019cites this paper
• Highly Sensitive Glycan Profiling of Hepatitis B Viral Particles and a Simple Method for Dane Particle Enrichment.

  2018cites this paper
• Antibody-mediated immunotherapy against chronic hepatitis B virus infection

  2017cites this paper
• Characteristics Peripheral Blood IgG and IgM Heavy Chain Complementarity Determining Region 3 Repertoire before and after Immunization with Recombinant HBV Vaccine

  2017cites this paper
• Localization of immunodominant epitopes within the “a” determinant of hepatitis B surface antigen using monoclonal antibodies

  2016cites this paper
• B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation

  2016cites this paper
• New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen.

  2016influential citation
• Functional assessment and structural basis of antibody binding to human papillomavirus capsid

  2016cites this paper
• Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy

  2016cites this paper
• Identification of Antigen-Specific B-Cell Receptor Sequences from the Total B-Cell Repertoire.

  2015cites this paper
• A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity

  2015cites this paper
• Validation of Cross-Genotype Neutralization by Hepatitis B Virus-Specific Monoclonal Antibodies by In Vitro and In Vivo Infection

  2015cites this paper
• Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen

  2014cites this paper
• Virus-like particle-based human vaccines: quality assessment based on structural and functional properties.

  2013cites this paper
• The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies

  2013cites this paper
• Replication-Competent Infectious Hepatitis B Virus Vectors Carrying Substantially Sized Transgenes by Redesigned Viral Polymerase Translation

  2013cites this paper
• Proteomics-directed cloning of circulating antiviral human monoclonal antibodies

  2012cites this paper
• [Single B cell monoclonal antibody technologies and applications].

  2012cites this paper
• Universal vaccination of hepatitis B virus vaccine

  2012cites this paper
• Single B cell antibody technologies

  2011cites this paper